TM
PMVP icon

Torren Management’s PMV Pharmaceuticals PMVP Stock Holding History

Torren Management’s Portfolio PMVP Stock Details PMVP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-4,716
Closed -$5.89K – 1326
2025
Q4 		$5.89K Buy
+4,716
New +$6.32K ﹤0.01% 879

Other funds holding PMVP

BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Torren Management's PMVP Position: Q1 2026 in Review

Torren Management sold out of PMV Pharmaceuticals (PMVP) in Q1 2026, closing a stake of 4,716 shares — an estimated $5.89K sold.

Torren Management first reported a position in PMVP in Q4 2025 and held it in 1 quarter. The position peaked at $5.89K in Q4 2025. 69 funds tracked by Wall St. Rank hold PMVP as of Q1 2026.

  • Torren Management reported no remaining PMV Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Torren Management sold 4,716 PMV Pharmaceuticals shares in Q1 2026, an estimated $5.89K.
  • Torren Management first reported a position in PMV Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Torren Management's PMV Pharmaceuticals position peaked at $5.89K in Q4 2025.
  • 69 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q1 2026.

Based on Torren Management's 13F filing for Q1 2026, filed 30 Apr 2026.